[CAS NO. 2971704-85-3] RXFP2 agonist 2
PRODUCTS SPECIFICATIONS [2971704-85-3]
DESCRIPTION [2971704-85-3]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 787.37 |
| Molecular Formula | C29H19F9IN3O5 |
| SMILES | O=C(N1[C@H]2CN(CC1)C(COC3=CC=C(C=C3I)OC(F)(F)F)=O)C4=CC(C5=CC(C(F)(F)F)=CC(C(F)(F)F)=C5)=CC=C4NC2=O |
Summary
RXFP2 agonist 2 is a selective and allosteric RXFP2 agonist with an EC 50 value of 0.38 µM. RXFP2 agonist 2 induces osteoblast mineralization. RXFP2 agonist 2 increases bone formation in female mice. RXFP2 agonist 2 has the potential for the research of osteoporosis [1] .
IC50 & Target
EC 50 : 0.38 µM (RXFP2) [1]
In Vitro
RXFP2 agonist 2 (Compound 6641) (1, 3, 5 µM; 14 days) induces osteoblast mineralization at 3 and 5 µM with no cytotoxicity in HCO cells [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Cytotoxicity Assay [1]
| Cell Line: | HCO cells |
| Concentration: | 0-100 µM |
| Incubation Time: | 14 days |
| Result: | Induced mineralization of primary human osteoblasts and is non-cytotoxic. |
In Vivo
RXFP2 agonist 2 (10 mg/kg; p.o.; 3 times per week for 8 weeks) promotes bone formation in female mice [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 8-week-old WT C57BL/6 J female mice [1] |
| Dosage: | 3 mg/kg for i.v.; 10 mg/kg for p.o. |
| Administration: | I.v. or p.o. |
| Result: | Exhibited a half-life of between 4-6.5 h depending on the route of administration, with no accumulation at 10 mg/kg, and oral bioavailability around 25-31%. |
| Animal Model: | 8-week-old WT C57BL/6 J female mice [1] |
| Dosage: | 10 mg/kg |
| Administration: | P.o.; 3 times per week for 8 weeks |
| Result: | Increased bone formation in mouse with significantly increased in Tb.N and Tb.Th, and increased BV/TV and decreased Tb.Sp. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.